Idera Pharmaceuticals to Present at BIO Business Forum and Participate in Toll-Like Receptor Panel at BIO 2007
03 Mai 2007 - 2:00PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced its
participation in two sessions at the 2007 BIO International
Convention taking place May 6-9, 2007 at the Boston Convention and
Exhibition Center in Boston, MA. Robert Karr, M.D., President of
Idera, will discuss the Company�s drug discovery and development
programs targeting Toll-like receptors and provide a general
corporate overview during the company presentation track at the BIO
Business Forum. The presentation will begin at 10:15 a.m. (ET) on
Tuesday, May 8, 2007 in Room E of the Business Forum. Sudhir
Agrawal, D. Phil., Chief Executive Officer and Chief Scientific
Officer of Idera, will participate in a panel entitled, �Toll-like
Receptor Modulation: Multiple Methods to Mine Diverse Therapeutic
Potential,� a session in the Drug Discovery & Development
track. The panel will begin at 2:00 p.m. (ET) on Wednesday, May 9,
2007 in Room 259 AB. About Idera Pharmaceuticals, Inc. Idera
Pharmaceuticals is a drug discovery and development company that is
developing drug candidates to treat cancer and infectious,
respiratory, and autoimmune diseases, and for use as vaccine
adjuvants. Idera�s proprietary drug candidates are designed to
modulate TLRs, the body�s first line of immune defense. Idera�s
pioneering DNA chemistry expertise enables it to identify drug
candidates for internal development and creates opportunities for
multiple collaborative alliances. Idera�s most advanced clinical
candidate, IMO-2055, is an agonist of TLR9 and is currently in a
Phase 2 trial in oncology and in a Phase 1/2 chemotherapy
combination trial in oncology. Idera has selected a second TLR9
agonist, IMO-2125, as a lead candidate for treating infectious
diseases. Idera is collaborating with Novartis International
Pharmaceutical, Ltd. for the discovery, development, and
commercialization of TLR9 agonists for the treatment of asthma and
allergy indications. Idera is also collaborating with Merck &
Co., Inc. for the use of Idera�s TLR7, 8 and 9 agonists in
combination with Merck�s therapeutic and prophylactic vaccines in
the areas of oncology, infectious diseases, and Alzheimer�s
disease. For more information, visit www.iderapharma.com. Forward
Looking Statements This press release contains forward-looking
statements concerning Idera Pharmaceuticals, Inc. that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Idera�s actual results to differ materially from those
indicated by such forward-looking statements, including whether
products based on Idera�s technology will advance into or through
the clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials or announce trial results in
the time expected; whether, if the Company�s products receive
approval, they will be successfully distributed and marketed;
whether the results of preclinical studies will be indicative of
results that may be obtained in clinical trials; whether the
Company�s collaborations with Novartis and Merck will be
successful; whether Idera�s cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera�s Annual Report on Form 10-K filed on March 30, 2007,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024